Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Peanut Allergy: early-phase trial registry
2 of 14 indexed Peanut Allergy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 2 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Peanut Allergy: 14 US clinical trials tracked, 2 recruiting.
Peanut Allergy is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Aimmune Therapeutics, running 5 of these trials.
Enrollment posture brief
Registry condition peanut-allergy
OPEN 2 | RECR 14% | LATE 5 | EARLY 9 | RANK #1230 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)
Peanut Allergy lists 2 open slots (14% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Peanut Allergy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Peanut Allergy is recruiting below its size-band peers.
2 of 14 indexed trials (14.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Peanut Allergy research.
Aimmune Therapeutics accounts for 5 of 14 trials (35.7%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Peanut Allergy enrolment sits around 90 participants.
Median target enrolment is 90 among the 14 trials that report a genuine target (sentinel values excluded). 8 of those (57.1%) plan for fewer than 100 participants.
-
Peanut Allergy research is mostly interventional.
14 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
DBV Technologies
NCT07003919
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
Rima Rachid
NCT05695261
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
ALK-Abelló A/S
NCT05440643
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
Aravax Pty
NCT05621317
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
Allergy Therapeutics
NCT05476497
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
Aimmune Therapeutics
NCT02635776
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
Aimmune Therapeutics
NCT03126227
Safety Study of Viaskin Peanut to Treat Peanut Allergy
DBV Technologies
NCT02916446
AR101 Real-World Open-Label Extension Study
Aimmune Therapeutics
NCT03337542
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
Scott Sicherer
NCT03907397
Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT
Aimmune Therapeutics
NCT01987817
Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study
Aimmune Therapeutics
NCT02198664
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
Boston Children's Hospital
NCT01781637
A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
Astellas Pharma Global Development
NCT02851277
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 5 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Peanut Allergy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Peanut Allergy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Peanut Allergy page
14 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Peanut Allergy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Aimmune Therapeutics sponsors the most Peanut Allergy trials on record, review their full trial history before evaluating a specific study. See Aimmune Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Peanut Allergy condition card totals 14 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.